Johnson & Johnson Oncology Sales Surge 17.8% in Q1, Darzalex Royalties Aid
Johnson & Johnson’s oncology sales rose 17.8% in Q1 driven by Darzalex, Erleada and new drug launches as it pursues a $50 billion cancer sales goal by 2030. The company also received higher Darzalex royalties following Genmab’s Q1 revenue expansion efforts.
1. Q1 Oncology Sales Growth
Johnson & Johnson’s oncology segment delivered 17.8% year-over-year sales growth in the first quarter, led by strong performance from Darzalex and newly launched therapies. Erleada added significant revenue alongside other recent cancer treatment approvals.
2. Darzalex Royalties Boost
J&J received increased Darzalex royalty payments after Genmab reported higher Q1 revenue driven by its global expansion push. These royalties underscore the ongoing collaboration’s contribution to J&J’s revenue.
3. $50B Cancer Sales Ambition
The company reaffirmed its target of reaching $50 billion in annual cancer sales by 2030, citing a deep pipeline and upcoming late-stage trial readouts. Management noted that planned regulatory filings and potential approvals will be critical to hitting this milestone.